title: Calcium supplements: benefits and risks.
abstract: Calcium is an essential element in the diet, but there is continuing controversy regarding its optimal intake, and its role in the pathogenesis of osteoporosis. Most studies show little evidence of a relationship between calcium intake and bone density, or the rate of bone loss. Re-analysis of data from the placebo group from the Auckland Calcium Study demonstrates no relationship between dietary calcium intake and rate of bone loss over 5 years in healthy older women with intakes varying from <400 to >1500 mg day(-1) . Thus, supplements are not needed within this range of intakes to compensate for a demonstrable dietary deficiency, but might be acting as weak anti-resorptive agents via effects on parathyroid hormone and calcitonin. Consistent with this, supplements do acutely reduce bone resorption and produce small short-term effects on bone density, without evidence of a cumulative density benefit. As a result, anti-fracture efficacy remains unproven, with no evidence to support hip fracture prevention (other than in a cohort with severe vitamin D deficiency) and total fracture numbers are reduced by 0-10%, depending on which meta-analysis is considered. Five recent large studies have failed to demonstrate fracture prevention in their primary analyses. This must be balanced against an increase in gastrointestinal side effects (including a doubling of hospital admissions for these problems), a 17% increase in renal calculi and a 20-40% increase in risk of myocardial infarction. Each of these adverse events alone neutralizes any possible benefit in fracture prevention. Thus, calcium supplements appear to have a negative risk-benefit effect, and so should not be used routinely in the prevention or treatment of osteoporosis.
authors.affiliation: Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.|Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand.
authors.forename: I R
authors.initials: IR
authors.lastname: Reid
authors.affiliation: Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
authors.forename: S M
authors.initials: SM
authors.lastname: Bristow
authors.affiliation: Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
authors.forename: M J
authors.initials: MJ
authors.lastname: Bolland
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000494:pharmacology; D002118:Calcium / Q000008:administration & dosage* / Q000009:adverse effects; D002137:Calculi / Q000209:etiology; D019587:Dietary Supplements; D050723:Fractures, Bone / Q000517:prevention & control; D041981:Gastrointestinal Tract / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D010024:Osteoporosis / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000494:pharmacology; D018570:Risk Assessment
chemical_list: D010281:Parathyroid Hormone; D002116:Calcitonin; D002118:Calcium
keywords: bone density; calcium balance; calcium intake; fracture; osteoporosis